Profile data is unavailable for this security.
About the company
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing ex vivo and in vivo cell engineering platforms to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including type 1 diabetes (T1D), B cell mediated autoimmune diseases, and oncology. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC451, SC291, SC262, SG299 and UP421. SC451 is a pluripotent stem cell (PSC)-derived hypoimmune pancreatic islet cell product candidate for the treatment of diabetes, with an initial focus on T1D. The Company is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B cell malignancies who have received prior CD19-directed CAR T therapy in non-Hodgkin's lymphoma.
- Revenue in USD (TTM)0.00
- Net income in USD-208.67m
- Incorporated2018
- Employees194.00
- LocationSana Biotechnology Inc188 East Blaine Street, Suite 400SEATTLE 98102United StatesUSA
- Phone+1 (206) 701-7914
- Fax+1 (302) 636-5454
- Websitehttps://sana.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Niagen Bioscience Inc | 107.93m | 14.11m | 890.10m | 104.00 | 65.61 | 16.01 | 59.75 | 8.25 | 0.1722 | 0.1722 | 1.35 | 0.7056 | 1.59 | 3.42 | 19.70 | 1,037,740.00 | 20.83 | -23.12 | 29.66 | -35.20 | 62.51 | 60.73 | 13.07 | -15.71 | 3.12 | -- | 0.0002 | -- | 19.18 | 16.56 | 273.15 | -- | -26.37 | -- |
| Sionna Therapeutics Inc | 0.00 | -66.32m | 901.46m | 48.00 | -- | 2.56 | -- | -- | -1.55 | -1.55 | 0.00 | 7.98 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.52 | -- | -- | -- |
| Sana Biotechnology Inc | 0.00 | -208.67m | 942.82m | 194.00 | -- | 4.51 | -- | -- | -0.8846 | -0.8846 | 0.00 | 0.9273 | 0.00 | -- | -- | 0.00 | -37.04 | -39.42 | -40.10 | -43.39 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.82 | -- | 5.06 | -- |
| Mineralys Therapeutics Inc | 0.00 | -188.51m | 944.39m | 51.00 | -- | 2.75 | -- | -- | -3.74 | -3.74 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -53.69 | -- | -56.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -147.31 | -- | -- | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -132.86m | 945.99m | 94.00 | -- | 3.59 | -- | -- | -1.88 | -1.88 | 0.00 | 3.09 | 0.00 | -- | -- | 0.00 | -44.76 | -36.70 | -47.38 | -38.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.96 | -- | 9.12 | -- |
| Spyre Therapeutics Inc | 0.00 | -208.93m | 946.95m | 65.00 | -- | 2.89 | -- | -- | -3.97 | -3.97 | 0.00 | 8.01 | 0.00 | -- | -- | 0.00 | -39.52 | -75.44 | -44.27 | -85.33 | -- | -- | -- | -3,540.66 | -- | -- | 0.00 | -- | -100.00 | -- | 38.60 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -47.14m | 948.48m | 42.00 | -- | 9.50 | -- | -- | -0.5559 | -0.5559 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -36.03 | -34.72 | -40.17 | -38.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.48 | -- | -- | -- |
| Nurix Therapeutics Inc | 88.38m | -207.32m | 951.03m | 286.00 | -- | 2.12 | -- | 10.76 | -2.61 | -2.61 | 1.11 | 5.86 | 0.1603 | -- | -- | 309,024.50 | -37.61 | -33.88 | -43.82 | -40.43 | -- | -- | -234.58 | -311.53 | -- | -- | 0.00 | -- | -29.15 | 11.88 | -34.47 | -- | 41.22 | -- |
| SS Innovations International Inc | 18.54m | -22.18m | 966.08m | 378.00 | -- | 23.82 | -- | 52.11 | -0.1283 | -0.1283 | 0.1072 | 0.2095 | 0.3924 | 1.18 | 4.53 | 49,045.45 | -46.95 | -77.47 | -69.50 | -137.45 | 34.86 | 23.69 | -119.66 | -169.09 | 2.22 | -- | 0.1593 | -- | 251.46 | -- | 8.27 | -- | 67.53 | -- |
| Lenz Therapeutics Inc | 0.00 | -47.74m | 976.39m | 42.00 | -- | 4.97 | -- | -- | -1.77 | -1.77 | 0.00 | 6.97 | 0.00 | -- | -- | 0.00 | -22.81 | -39.77 | -24.41 | -42.56 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 60.07 | -- | -- | -- |
| Verve Therapeutics Inc | 59.61m | -181.01m | 983.25m | 274.00 | -- | 2.07 | -- | 16.49 | -2.11 | -2.11 | 0.6921 | 5.33 | 0.0885 | -- | 16.64 | 217,565.70 | -26.89 | -32.40 | -28.66 | -34.32 | -- | -- | -303.64 | -1,568.90 | -- | -- | 0.00 | -- | 174.98 | -- | 0.6793 | -- | 15.01 | -- |
| MiMedx Group Inc | 352.38m | 39.96m | 983.70m | 837.00 | 24.83 | 4.85 | 20.30 | 2.79 | 0.2682 | 0.2697 | 2.36 | 1.37 | 1.43 | 2.62 | 5.91 | 420,998.80 | 16.24 | 2.94 | 19.62 | 3.89 | 81.94 | 83.00 | 11.34 | 2.07 | 4.13 | -- | 0.0843 | -- | 8.52 | 3.12 | -24.73 | -- | -5.37 | -- |
| GH Research PLC | 0.00 | -42.11m | 984.39m | 50.00 | -- | 3.17 | -- | -- | -0.7878 | -0.7878 | 0.00 | 5.00 | -- | -- | -- | 0.00 | -- | -12.39 | -- | -12.66 | -- | -- | -- | -- | -- | -- | 0.0021 | -- | -- | -- | -9.48 | -- | -- | -- |
| Arcus Biosciences Inc | 141.00m | -391.00m | 987.91m | 627.00 | -- | 1.86 | -- | 7.01 | -4.19 | -4.19 | 1.51 | 5.01 | 0.1152 | -- | 4.62 | 224,880.40 | -31.93 | -16.91 | -38.09 | -19.76 | -- | -- | -277.31 | -97.85 | -- | -- | 0.0829 | -- | 120.51 | 76.65 | 7.82 | -- | 25.53 | -- |
| Zymeworks Inc | 93.38m | -113.68m | 998.43m | 299.00 | -- | 2.88 | -- | 10.69 | -1.50 | -1.50 | 1.24 | 4.63 | 0.1907 | -- | 3.36 | 333,514.30 | -23.22 | -19.80 | -26.52 | -23.38 | -- | -- | -121.73 | -80.81 | -- | -- | 0.00009 | -- | 0.3842 | 20.90 | -3.39 | -- | -26.07 | -- |
Data as of Jul 11 2025. Currency figures normalised to Sana Biotechnology Inc's reporting currency: US Dollar USD
39.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2025 | 29.21m | 13.08% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 10.28m | 4.61% |
| Baillie Gifford & Co.as of 31 Mar 2025 | 10.19m | 4.57% |
| Canada Pension Plan Investment Boardas of 31 Mar 2025 | 10.18m | 4.56% |
| The Vanguard Group, Inc.as of 31 Mar 2025 | 7.59m | 3.40% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 5.49m | 2.46% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2025 | 5.45m | 2.44% |
| Citadel Advisors LLCas of 31 Mar 2025 | 3.40m | 1.52% |
| Geode Capital Management LLCas of 31 Mar 2025 | 3.28m | 1.47% |
| Crestline Management LPas of 31 Mar 2025 | 2.79m | 1.25% |
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
